Isolated adrenal metastectomy has a low morbidity rate irrespective of performing surgical sub-specialty

Kristen E. Gurtner, Danica N. May, Jay D. Raman, Kathleen Lata-Arias, Daniel J. Canter

Research output: Contribution to journalArticle

Abstract

INTRODUCTION: There has been growing use of adrenalectomy as a potentially curative treatment option for patients with oligometastatic disease to the adrenal gland. We sought to compare the perioperative outcomes of patients undergoing isolated adrenalectomy in the setting of disseminated cancer using the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) database. Furthermore, we examined the impact of performing surgical sub-specialty on outcomes. MATERIALS AND METHODS: Data from the ACS-NSQIP database was obtained for patients between 2011 and 2016 who underwent adrenalectomy. Patients were stratified by the presence or absence of disseminated cancer. Univariate and multivariate regression analyses were performed to test for an association between the presence or absence of disseminated cancer and perioperative outcomes. The relationship between performing specialist and outcomes was also compared. RESULTS: A total of 4,207 patients were identified, with 270 (6.4%) in the disseminated cancer group. There was no significant difference in perioperative outcomes between patients with disseminated cancer and without disseminated cancer. On multivariate analysis, neither the presence of disseminated cancer (p = 0.47) nor the surgical sub-specialty performing adrenalectomy (p = 0.52) were associated with an increased risk postoperative morbidity or mortality. Of note, there was a statistically significant increase in the number of adrenalectomies performed by urologists in the setting of disseminated cancer (19.3% versus 10.4%, p < 0.01). CONCLUSIONS: Patients undergoing adrenalectomy in the setting of disseminated cancer did not have significantly worse perioperative outcomes compared to patients undergoing adrenalectomy for other indications. The adverse perioperative event rate was similar whether the operation was performed by a urologist or a general surgeon.

Original languageEnglish (US)
Pages (from-to)9931-9937
Number of pages7
JournalThe Canadian journal of urology
Volume26
Issue number5
StatePublished - Oct 1 2019

Fingerprint

Surgical Specialties
Adrenalectomy
Morbidity
Neoplasms
Quality Improvement
Adrenal Gland Diseases
Multivariate Analysis
Databases
Regression Analysis

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

Gurtner, Kristen E. ; May, Danica N. ; Raman, Jay D. ; Lata-Arias, Kathleen ; Canter, Daniel J. / Isolated adrenal metastectomy has a low morbidity rate irrespective of performing surgical sub-specialty. In: The Canadian journal of urology. 2019 ; Vol. 26, No. 5. pp. 9931-9937.
@article{7deb90a4a4774cf19ab86e53559f1455,
title = "Isolated adrenal metastectomy has a low morbidity rate irrespective of performing surgical sub-specialty",
abstract = "INTRODUCTION: There has been growing use of adrenalectomy as a potentially curative treatment option for patients with oligometastatic disease to the adrenal gland. We sought to compare the perioperative outcomes of patients undergoing isolated adrenalectomy in the setting of disseminated cancer using the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) database. Furthermore, we examined the impact of performing surgical sub-specialty on outcomes. MATERIALS AND METHODS: Data from the ACS-NSQIP database was obtained for patients between 2011 and 2016 who underwent adrenalectomy. Patients were stratified by the presence or absence of disseminated cancer. Univariate and multivariate regression analyses were performed to test for an association between the presence or absence of disseminated cancer and perioperative outcomes. The relationship between performing specialist and outcomes was also compared. RESULTS: A total of 4,207 patients were identified, with 270 (6.4{\%}) in the disseminated cancer group. There was no significant difference in perioperative outcomes between patients with disseminated cancer and without disseminated cancer. On multivariate analysis, neither the presence of disseminated cancer (p = 0.47) nor the surgical sub-specialty performing adrenalectomy (p = 0.52) were associated with an increased risk postoperative morbidity or mortality. Of note, there was a statistically significant increase in the number of adrenalectomies performed by urologists in the setting of disseminated cancer (19.3{\%} versus 10.4{\%}, p < 0.01). CONCLUSIONS: Patients undergoing adrenalectomy in the setting of disseminated cancer did not have significantly worse perioperative outcomes compared to patients undergoing adrenalectomy for other indications. The adverse perioperative event rate was similar whether the operation was performed by a urologist or a general surgeon.",
author = "Gurtner, {Kristen E.} and May, {Danica N.} and Raman, {Jay D.} and Kathleen Lata-Arias and Canter, {Daniel J.}",
year = "2019",
month = "10",
day = "1",
language = "English (US)",
volume = "26",
pages = "9931--9937",
journal = "Canadian Journal of Urology",
issn = "1195-9479",
publisher = "Canadian Journal of Urology",
number = "5",

}

Isolated adrenal metastectomy has a low morbidity rate irrespective of performing surgical sub-specialty. / Gurtner, Kristen E.; May, Danica N.; Raman, Jay D.; Lata-Arias, Kathleen; Canter, Daniel J.

In: The Canadian journal of urology, Vol. 26, No. 5, 01.10.2019, p. 9931-9937.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Isolated adrenal metastectomy has a low morbidity rate irrespective of performing surgical sub-specialty

AU - Gurtner, Kristen E.

AU - May, Danica N.

AU - Raman, Jay D.

AU - Lata-Arias, Kathleen

AU - Canter, Daniel J.

PY - 2019/10/1

Y1 - 2019/10/1

N2 - INTRODUCTION: There has been growing use of adrenalectomy as a potentially curative treatment option for patients with oligometastatic disease to the adrenal gland. We sought to compare the perioperative outcomes of patients undergoing isolated adrenalectomy in the setting of disseminated cancer using the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) database. Furthermore, we examined the impact of performing surgical sub-specialty on outcomes. MATERIALS AND METHODS: Data from the ACS-NSQIP database was obtained for patients between 2011 and 2016 who underwent adrenalectomy. Patients were stratified by the presence or absence of disseminated cancer. Univariate and multivariate regression analyses were performed to test for an association between the presence or absence of disseminated cancer and perioperative outcomes. The relationship between performing specialist and outcomes was also compared. RESULTS: A total of 4,207 patients were identified, with 270 (6.4%) in the disseminated cancer group. There was no significant difference in perioperative outcomes between patients with disseminated cancer and without disseminated cancer. On multivariate analysis, neither the presence of disseminated cancer (p = 0.47) nor the surgical sub-specialty performing adrenalectomy (p = 0.52) were associated with an increased risk postoperative morbidity or mortality. Of note, there was a statistically significant increase in the number of adrenalectomies performed by urologists in the setting of disseminated cancer (19.3% versus 10.4%, p < 0.01). CONCLUSIONS: Patients undergoing adrenalectomy in the setting of disseminated cancer did not have significantly worse perioperative outcomes compared to patients undergoing adrenalectomy for other indications. The adverse perioperative event rate was similar whether the operation was performed by a urologist or a general surgeon.

AB - INTRODUCTION: There has been growing use of adrenalectomy as a potentially curative treatment option for patients with oligometastatic disease to the adrenal gland. We sought to compare the perioperative outcomes of patients undergoing isolated adrenalectomy in the setting of disseminated cancer using the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) database. Furthermore, we examined the impact of performing surgical sub-specialty on outcomes. MATERIALS AND METHODS: Data from the ACS-NSQIP database was obtained for patients between 2011 and 2016 who underwent adrenalectomy. Patients were stratified by the presence or absence of disseminated cancer. Univariate and multivariate regression analyses were performed to test for an association between the presence or absence of disseminated cancer and perioperative outcomes. The relationship between performing specialist and outcomes was also compared. RESULTS: A total of 4,207 patients were identified, with 270 (6.4%) in the disseminated cancer group. There was no significant difference in perioperative outcomes between patients with disseminated cancer and without disseminated cancer. On multivariate analysis, neither the presence of disseminated cancer (p = 0.47) nor the surgical sub-specialty performing adrenalectomy (p = 0.52) were associated with an increased risk postoperative morbidity or mortality. Of note, there was a statistically significant increase in the number of adrenalectomies performed by urologists in the setting of disseminated cancer (19.3% versus 10.4%, p < 0.01). CONCLUSIONS: Patients undergoing adrenalectomy in the setting of disseminated cancer did not have significantly worse perioperative outcomes compared to patients undergoing adrenalectomy for other indications. The adverse perioperative event rate was similar whether the operation was performed by a urologist or a general surgeon.

UR - http://www.scopus.com/inward/record.url?scp=85073622555&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073622555&partnerID=8YFLogxK

M3 - Article

C2 - 31629442

AN - SCOPUS:85073622555

VL - 26

SP - 9931

EP - 9937

JO - Canadian Journal of Urology

JF - Canadian Journal of Urology

SN - 1195-9479

IS - 5

ER -